Categories Cancer Risk
Search Results for Categories Cancer Risk page 9
Relevance: Medium-High
Most relevant for: Nigerian women or women of Nigerian descent who have breast cancer
Study: Inherited breast cancer in Nigerian women
A new study shows that among Nigerian women, one in eight cases of breast cancer is due to an inherited mutation in BRCA1, BRCA2, PALB2 or TP53. (12/5/18)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with an inherited mutation linked to cancer
Personal Story: Pamela Munster's story of cancer in the family
In her essay in The Washington Post, Dr. Pamela Munster recounts her family's history with cancer associated with a mutation in the BRCA2 gene. She details her father's extraordinary journey with pancreatic cancer, one of the most aggressive and deadly cancers. (11/27/18)
READ MORE ›
Relevance: Medium-Low
Most relevant for: People who have a Variant of Uncertain Significance in a gene associated with cancer risk.
Study: A new method for determining whether genetic variants in BRCA1 increase cancer risk
Ever since BRCA1 was discovered, researchers have been trying to understand which of the thousands of possible DNA changes in this gene increase cancer risk and which are harmless changes. A new study in Nature reports how a cutting-edge technology called “genome editing” may be used to classify changes—known as variants of uncertain significance-in BRCA1 as harmful or harmless. Once validated, this same technology may be used to classify variants in other genes. (9/29/18)
READ MORE ›
Relevance: Medium-High
Most relevant for: Women with an inherited mutation linked to increased risk for cancer
Article: Cancer experience in families affects decision making
Women with inherited mutations in genes that increase breast and ovarian cancer risk have an additional challenge: coping with how those mutations impact their families and how a family member’s cancer experience can shape their own perception. In a recent U.S. News and World Report article, Elaine Howley explores how a woman's decisions about healthcare, cancer prevention and treatment are affected by experience with cancer in the family. (9/25/18)
READ MORE ›
Relevance: Medium-High
Most relevant for: Women with BRCA1 mutations who have had risk-reducing ovary removal and have never been diagnosed with breast cancer
Study: Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation
Does hormone therapy (HT) alter the risk of breast cancer for woman carrying a BRCA1 mutation who have never been diagnosed with cancer? In this study, researchers showed that among women with BRCA1 mutations, HT use did not increase breast cancer rates for 10 years after ovary removal. More women taking combined estrogen plus progesterone developed breast cancer compared to those taking estrogen only, though this difference was not statistically significant. (9/7/18)
Relevance: Medium-High
Most relevant for: People diagnosed with triple-negative breast cancer
Study: Study identifies genes associated with risk of triple-negative breast cancer
Panel testing can identify women who are at increased risk for breast cancer. However, those at risk for triple-negative breast cancer cannot easily be identified because other than BRCA1, genes that increase the risk for triple-negative breast cancer are unknown. A new study uses panel testing to identify which genes increase the risk for triple-negative breast cancer. (8/23/18)
READ MORE ›
Relevance: High
Most relevant for: Women at average risk for breast cancer
Study: Disparities in research impact breast screening guidelines
For women at average risk of breast cancer, the United States Preventive Services Task Force (USPSTF) currently recommends beginning annual breast cancer screening at age 50. However, because these guidelines are largely based on data from white women, they may not be sensitive to racial differences. A new study assesses the age distribution of breast cancer cases across race/ethnicity in the U.S. (6/21/18)
READ MORE ›
Relevance: High
Most relevant for: People with Icelandic heritage
Article: The right not to know when not knowing is dangerous
Healthcare providers are bound by the guiding principle of doing no harm. But how does this concept apply to their patients who have not consented to genetic testing or who do not want to know their results? In that case, is providing test results more harmful or not? Anna Clausen explores these issues in the context of breast cancer gene testing in her Global Health Now article “The Right Not to Know: When Ignorance is Bliss but Deadly.” (4/20/18)
READ MORE ›
Relevance: Medium
Most relevant for: People who are considering or have had direct-to-consumer testing through 23andMe
Update: FDA approves at-home test kits for inherited cancer: how useful are they?
Genetic testing for health conditions (such as risk for cancer) typically requires a prescription from a doctor. Until recently, direct-to-consumer (DTC) genetic testing has focused on tests to learn your ancestry and find of unknown branches of family trees. A laboratory called 23andMe that provides direct-to-consumer genetic testing has been given FDA approval to report results for 3 mutations found in the BRCA1 and BRCA2 genes. The FDA statement provides details about this approval and warns people about the limitations of the 23andMe test. (03/19/18)
READ MORE ›
Relevance: Medium-High
Most relevant for: People considering testing for an inherited gene mutation
Article: Insurance companies are more than curious about your genetic test results
An article on CBSNews.com addressed why insurance companies, particularly long-term insurance companies, might want to know which of their policy holders and potential policy holders have a gene that raises their risk for cancer. The article discusses genetic discrimination by insurance companies that provide long term care policies. Federal laws protect people with gene mutations from discrimination in health insurance. No such federal laws exist for life insurance, disability insurance or long term care. (3/13/18)
READ MORE ›